A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.

The objectives of this trial are to evaluate the tolerability and safety of crizotinib in Japanese patients with recurrent/refractory ALK-positive ALCL or neuroblastoma (phase I) and its efficacy in recurrent/refractory ALK-positive ALCL (phase II). PMID: 30140094 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30140094?dopt=Abstract

Source: Acta Medica Okayama - August 25, 2018 Category: General Medicine Tags: Acta Med Okayama Source Type: research